TerminatedNCT04757636
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
PHASE3 · 998 planned enrolment
- Countries listed
- 30
- Registry update
- August 5, 2025
immortal.lifeTrial registrations containing the exact intervention label 2.0 mg OPT-302.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE3 · 998 planned enrolment
PHASE3 · 986 planned enrolment